Explore how changing treatment trends and industry competition are influencing ResMed’s future outlook, innovation strategy, ...
ResMed remains in focus as competition, sleep health innovation, and long-term treatment demand shape the company's evolving ...
ResMed(NYSE: RMD), amedical device company focused on sleep apnea and chronic obstructive pulmonary disease, reported its first-quarter results after the market closed on Thursday, April 27. While ...
Resmed said Monday it has closed the $340 million takeover of Noctrix Health, adding a device to treat restless legs syndrome ...
CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) shares are down in the the dumps. Is now the time to buy? Let's find ...
Medical Device Network on MSN
ResMed completes $340M Noctrix Health acquisition
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results